6676.Two
6676.TWO is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the oncology and immunology therapeutic areas.
Business. 6676.TWO is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the oncology and immunology therapeutic areas.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6676.TWO is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the oncology and immunology therapeutic areas.
6676.TWO has a market capitalization of TWD 20.61 billion and an enterprise value to revenue ratio of 9.79, indicating a moderate valuation relative to its revenue. The company's liquidity position is characterized as medium risk, with cash and equivalents of TWD 47.77 million and long-term debt of TWD 463.62 million, resulting in a debt-to-equity ratio of 0.61. The negative operating cash flow of TWD -158.99 million suggests ongoing cash burn, which could pressure liquidity if not offset by financing or operational improvements.
Profitability metrics show mixed performance. The company's return on invested capital (ROIC) and operating margin are not disclosed, but the negative operating cash flow indicates challenges in converting revenue into cash. The pharmaceutical industry typically prioritizes research and development (R&D) investment and long-term revenue visibility, but 6676.TWO's current financials suggest a focus on sustaining operations rather than aggressive growth.
The company's revenue is concentrated in undisclosed segments and geographic regions, as no segment or geographic breakdown is provided in the available data. This lack of transparency limits the ability to assess diversification risk or growth potential in specific markets.
Looking ahead, the company's growth trajectory is uncertain. No specific revenue growth rates or outlooks are provided in the available data, and the negative operating cash flow suggests a need for operational or financing improvements to support future growth.
The risk assessment highlights liquidity as a medium concern, with the company's net cash position being negative after subtracting total debt. The dilution risk is assessed as low, but the company's capital structure and financing activities should be monitored for any changes that could affect shareholder value.
Recent events and filings are not detailed in the available data, so no specific recent developments can be cited. The company's financial health and strategic direction will depend on its ability to manage cash flow, reduce debt, and potentially increase revenue through product development or market expansion.
- 6676.TWO has a moderate valuation with an EV/Revenue of 9.79, but its liquidity position is at medium risk due to negative operating cash flow and significant long-term debt.
- The company's debt-to-equity ratio of 0.61 suggests a relatively balanced capital structure, but the negative net cash position indicates potential liquidity constraints.
- The lack of segment and geographic revenue breakdown limits the ability to assess diversification and exposure to specific markets.
- The company's growth trajectory is unclear, with no specific revenue growth rates or outlooks provided in the available data.
- The risk assessment highlights liquidity as a medium concern, with the company's net cash position being negative after subtracting total debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- 6676.TWO Market data — financials · 2026-05-27